Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-533 · 1 trial · 1 indication
RP2D as determined by interval 3+3 dose escalation design
Safety and tolerability of ORIC-533
Safety and tolerability of ORIC-533
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ORIC-533 dosed orally, once per day of each consecutive 28-day cycle. |
| Dose Expansion | EXPERIMENTAL | RP2D dose |
| Name | Type | Description |
|---|---|---|
| ORIC-533 | DRUG | ORIC-533 once daily in consecutive 28-day cycles |
Inclusion Criteria: * Diagnosis of multiple myeloma (MM) with relapsed or refractory disease according to IMWG Criteria * Refractory to or not eligible for MM treatment regimens known to provide clinical benefit, including but not limited to an immunomodulatory agent, a proteasome inhibitor, and an...
Top 20 of 25 competitors
ORIC-533 is an investigational small molecule being studied for the treatment of relapsed or refractory multiple myeloma, a type of blood cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ORIC-533 is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ORIC. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ORIC-533 is in Phase 1 clinical development. A Phase 1 study of ORIC-533 in relapsed or refractory multiple myeloma has been completed, involving 31 participants. The drug remains investigational and is not yet approved for any use.
ORIC-533 has been studied in a Phase 1 clinical trial identified as NCT05227144, titled 'Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma.' This trial enrolled 31 participants and was conducted in the United States and Canada. The trial has been completed.
ORIC-533 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for relapsed or refractory multiple myeloma. A completed Phase 1 trial has evaluated its safety and tolerability, but it has not yet received regulatory approval.